Drug profile · INN
ansuvimab-zykl
EBANGA
ansuvimab-zykl (EBANGA) is a envelope glycoprotein binding agent. Route of administration: iv (infusion). Current US regulatory status: approved.
Drug details — ansuvimab-zykl
- US status
- approved
- Class
- —
- Route
- IV (INFUSION)
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ansuvimab-zykl (EBANGA) is a envelope glycoprotein binding agent. Route of administration: iv (infusion). Current US regulatory status: approved.
Key facts
Mechanism of action
Envelope glycoprotein binding agent
Primary target: Envelope glycoprotein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ansuvimab-zykl?
ansuvimab-zykl (EBANGA) is a envelope glycoprotein binding agent. Route of administration: iv (infusion). Current US regulatory status: approved.
What is the brand name for ansuvimab-zykl?
EBANGA is a marketed brand name for ansuvimab-zykl. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ansuvimab-zykl?
ansuvimab-zykl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.